Product Description
AZD0171 is a monoclonal antibody that binds to LIF and prevents signaling through LIF receptor. A murine surrogate of AZD0171 (mAZD0171) was generated and tested in vivo using three syngeneic murine cancer models, and AZD0171 was tested in patient derived xenograft models. (Sourced from: https://aacrjournals.org/cancerres/article/82/12_Supplement/1293/700918/Abstract-1293-AZD0171-anti-LIF-combines#:~:text=AZD0171%20is%20a%20monoclonal%20antibody,in%20patient%20derived%20xenograft%20models.)
Mechanisms of Action: WEE1 Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, France, Hungary, Ireland, Italy, Korea, Portugal, Spain, Taiwan, Turkey, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Adenocarcinoma|Leukemia|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NeoCOAST-2 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2028-12-22 |
|
| D8151C00001 | P2 |
Active, not recruiting |
Leukemia|Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma |
2024-10-07 |
|
| 2021-002040-78 | P2 |
Active, not recruiting |
Pancreatic Ductal Carcinoma|Adenocarcinoma|Pancreatic Cancer |
2023-12-05 |